A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza

NCT05052697 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

1158

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza, Human

Interventions

BIOLOGICAL: mIRV
BIOLOGICAL: bIRV AB
BIOLOGICAL: qIRV
BIOLOGICAL: QIV
BIOLOGICAL: bIRV AA
BIOLOGICAL: bIRV BB

Sponsor

Pfizer